API | ozenoxacin

ozenoxacin (xepi) Report issue

Small molecule Approved ^FDA

AACT DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW

Ozenoxacin is an experimental quinolone antibiotic being developed for the treatment of impetigo and other dermatological bacterial infections. Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics. In two phase 3 studies, Ozenoxacin cream, 1%, applied topically twice daily for 5 days vs. placebo, demonstrated superiority on both clinical and bacteriological endpoints, according to the release. Superior bacteriological cure of Ozenoxacin compared to placebo was demonstrated as early as day 4. In both adults and a pediatric population aged 2 months and older, Ozenoxacin treatment was reported to be safe and well tolerated. ^NCATS

Chemistry

SMILES: CNc1ncc(cc1C)c2ccc3C(=O)C(=CN(C4CC4)c3c2C)C(=O)O
InChIKey: XPIJWUTXQAGSLK-UHFFFAOYSA-N
Mol. Mass: 363.42
ALogP: 3.76 Partition coefficient
ChEMBL Molecule:
ozenoxacin

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA gyrase subunit A (Staphylococcus aureus) ^UniProt
- DNA gyrase subunit B (Staphylococcus aureus) ^UniProt
- DNA gyrase subunit A (Streptococcus pyogenes serotype M3 (strain ATCC BAA-595 / MGAS315)) ^UniProt
- DNA gyrase subunit B (Streptococcus pyogenes serotype M3 (strain ATCC BAA-595 / MGAS315)) ^UniProt
- DNA topoisomerase 4 subunit A (Streptococcus pyogenes serotype M3 (strain ATCC BAA-595 / MGAS315)) ^UniProt
- DNA topoisomerase 4 subunit B (Streptococcus pyogenes serotype M3 (strain ATCC BAA-595 / MGAS315)) ^UniProt
- DNA topoisomerase 4 subunit A (Staphylococcus aureus) ^UniProt
- DNA topoisomerase 4 subunit B (Staphylococcus aureus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Topical
Pro Drug: No

1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid | gf-001001-00 | ozenoxacin | t 3912 | t-3912 | zebiax

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (1)

Impetigo

Experimental Indications - Clinical Trial Phases 1-4 (2)

Impetigo (Phase 3)

Traumatology (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue